IRMD icon

iRadimed

60.85 USD
-0.33
0.54%
Updated Feb 12, 11:13 AM EST
1 day
-0.54%
5 days
-3.41%
1 month
7.68%
3 months
6.85%
6 months
38.30%
Year to date
10.76%
1 year
33.41%
5 years
137.42%
10 years
306.75%
 

About: iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

Employees: 148

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

70% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 37

47% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 15

12% more capital invested

Capital invested by funds: $304M [Q2] → $340M (+$36.4M) [Q3]

4% more funds holding

Funds holding: 137 [Q2] → 143 (+6) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

1.16% less ownership

Funds ownership: 54.64% [Q2] → 53.48% (-1.16%) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for IRMD.

Financial journalist opinion

Neutral
GlobeNewsWire
1 week ago
IRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025
WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market opens on Thursday, February 13, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
IRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025
Neutral
GlobeNewsWire
1 month ago
IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging compatible medical devices, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2024.
IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
Positive
Zacks Investment Research
1 month ago
iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why
Neutral
GlobeNewsWire
1 month ago
IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference.
IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Positive
Zacks Investment Research
2 months ago
Here's Why Momentum in iRadimed (IRMD) Should Keep going
iRadimed (IRMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's Why Momentum in iRadimed (IRMD) Should Keep going
Neutral
GlobeNewsWire
2 months ago
IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025
WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), today announced it has been ranked 24th on Forbes' list of America's Most Successful Small-Cap Companies 2025. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025
Positive
Zacks Investment Research
3 months ago
iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable
Neutral
GlobeNewsWire
3 months ago
IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024
WINTER SPRINGS, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named one of Fortune's 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024
Neutral
Seeking Alpha
3 months ago
IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript
IRADIMED CORPORATION. (NASDAQ:IRMD ) Q3 2024 Earnings Conference Call October 31, 2024 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH Capital Partners Operator Welcome to the IRadimed Corporation Third Quarter of 2024 Financial Results Conference Call.
IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
3 months ago
IRadimed (IRMD) Beats Q3 Earnings and Revenue Estimates
IRadimed (IRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.43 per share a year ago.
IRadimed (IRMD) Beats Q3 Earnings and Revenue Estimates
Charts implemented using Lightweight Charts™